

DEA CAPITAL

BUY

1.84

SECTOR: Holdings & RE

Price (Eu):

Micaela Ferruta +39-02-77115.428 e-mail: ferruta@intermonte.it

Target Price (Eu): 2.55

Well on Track to Accomplish Business Plan


- 1H08 Results are not significant for DeA Capital, but they were in line with our estimates. NAV stood at Eu2.78ps. The same calculation, with GDS and Migros at market prices, would yield a NAV of Eu2.14p.s. However, GDS stock price, which has the biggest impact, is no longer significant, as the real market float is extremely thin. Net cash stood at Eu262mn (vs. Eu266mn expected); we expect NFP to decline to Eu93mn cash, accounting for the acquisitions carried out in 2H08.
- Taking a look at the results of the operating companies and the new deals.
 - GDS reported results in July, with revenues up 4% YoY in 1H08, slightly below our expectations for FY08, despite strongly outperforming market growth (+2.8% YoY). In July, the company also announced the sale and lease back of over Eu200mn of real estate and some new acquisitions, while some of the Italian assets have been sold.
 - MIGROS TURK reported results which are above budget and consensus (we did not have estimates). What's more, the JV which acquired the majority in February has increased its stake from 50.8% to 81.6%, buying shares on the market, and will launch a mandatory take over on the remaining shares soon;
 - <u>First Atlantic</u> the acquisition will be completed in 4Q08 and therefore results are not consolidated;
 - IDEA ALTERNATIVE INVESTMENTS reported Eu4.4mn net income in 1H08 (but is only consolidated from 2Q08);
 - SIGLA reported strong YoY growth in outstanding loans (+26.6%), though this is below long term targets and our estimates
- We reiterate our BUY rating on the stock, target price Eu2.55. The stock has performed well over the last 6 months, partly sustained by the buyback but above all, thanks to a quick execution of the Eu1.1bn investment plan. On the back of operating companies' results, we have revised estimates and valuations, and confirm our target price of Eu2.55, which is calculated applying a 15% discount to the adjusted NAV (averaging fair values of the assets with the market price or book value). Net of this, we would reach a per share valuation of Eu3.36.
- In order to eliminate or reduce the discount currently applied to the NAV by the market and to a lesser extent by us, we believe that, apart from further improving the performance of participated companies, in line with or above plans, the company should de-list assets, chiefly 1)Générale de Santé (still seen as a priority by the management) and 2) Migros (already underway), 3) potentially utilise the Eu120mn in losses, which are not expiring; 4) simplify the structure, part of which has been completed, possibly via breaking up the company, separating the Direct investment business from the Indirect one (IDEA and First Atlantic). This last possibility is not on the cards, however.

KeyFigures	2006A	2007A	2008E	2009E	2010E
EBIT (Eu mn)	(5)	(4)	(0)	18	18
Net profit (Eu mn)	86	6	0	18	27
EPS - New (Eu)	0.49	0.03	0.00	0.06	0.09
EPS - Old (Eu)	0.49	0.02	0.04	0.09	0.11
DPS (Eu)	0.00	0.00	0.00	0.00	0.00
NAVPS (Eu)	1.51	2.77	2.77	2.83	2.91

Ratios & Multiples	2006A	2007A	2008E	2009E	2010E
P/E	3.8	72.4	nm	31.3	21.2
Div. Yield	0.0%	0.0%	0.0%	0.0%	0.0%
P/NAVPS	1.2	0.7	0.7	0.6	0.6
ROCE					

The reproduction of the information, recommendations and research produced by Intermonte SIM contained herein, and of any of its parts, is strictly prohibited. None of the contents of this document may be shared with third parties without Company authorization.

DEA CAPITAL - 12m Performance



RATING: Unchanged

TARGET PRICE (Eu): Unchanged

Change in EPS est: 2008E 2009E
-101.8% -34.4%

STOCK DATA

12 months H/L

Reuters code:		DEA.MI	
Bloomberg code:		DEA IM	
Performance	1m	3m	12m
Absolute	-5.0%	6.5%	-33.9%
Relative	-3.3%	21.5%	-3.1%

2 77/1 54

12 MONUS II/ E.	2.7771.5-
SHAREHOLDER DATA	
No. of Ord. shares (mn):	307
Total No. of shares (mn):	307
Mkt Cap Ord (Eu mn):	563
Total Mkt Cap (Eu mn):	563
Mkt Float - ord (Eu mn):	196
Mkt Float (in %):	34.9%
Main shareholder:	
De Agostini	60.3%
BALANCE SHEET DATA	2008

 BALANCE SHEET DATA
 2008

 Book value (Eu mn):
 849

 BVPS (Eu):
 2.77

 P/BV:
 0.7

 Net Debt (#BadKeyword mn):
 -93

 NAV (Eu mn)
 849



CAPITAL - KEY FIGURES		2006A	2007A	2008E	2009E	2010
	Fiscal year end	31/12/2006	31/12/2007	31/12/2008	31/12/2009	31/12/2010
PROFIT & LOSS (Eu mn)	Sales	1	0	8	38	39
, ,	EBITDA	(5)	(4)	(0)	18	18
	EBIT	(5)	(4)	(0)	18	1
	Financial income (charges)	13	14	10	5	
	Associates & Others	1	(5)	(5)	8	1!
	Pre-tax profit (loss)	11	5	5	30	3
	Taxes	(0)	(1)	(5)	(8)	(8)
	Tax rate (%)	1.2%	15.9%	92.3%	25.7%	20.59
	Minorities & discontinue activities	76	2	(1)	(4)	(4
	Net profit	86	6	0	18	2
	Total extraordinary items			.		
	Ebitda exd. extraordinary items	(5)	(4)	(0)	18	1
	Ebit excl. extraordinary items	(3)	(4)	(0)	10	
	Net profit restated	86	6	(0)	18	2
PER SHARE DATA (Eu)	Total shares out (mn) - average fd	177	307	307	307	30
	EPS stated fd	0.49	0.03	0.00	0.06	0.0
	EPS restated fd	0.49	0.03	0.00	0.06	0.0
	BVPS fd	1.51	2.77	2.77	2.83	2.9
	NAVPS fd	1.51	2.77	2.77	2.83	2.9
	Dividend per share (ord)	0.00	0.00	0.00	0.00	0.0
	Dividend pay out ratio (%)	0.0%	0.0%	0.0%	0.0%	0.0
CASH FLOW (Eu mn)	Change in NWC	0	0	0	0	
57151112511 (Ed 11111)	Capital expenditure	0	0	0	0	
	Other cash items	0	0	0	0	
	Free cash flow (FCF)	0	0	0	0	
	Acquisitions, divestments & other	3	· ·	· ·	Ü	
	Dividend					
	Change in Net Financial Position		178	(323)	20	2
		20		756	754	
BALANCE SHEET (Eu mn)	Total fixed assets	29	444			75
	Net working capital	(1)	(11)	0	0	
	Long term liabilities					
	Net capital employed	29	433	756	754	75
	Net financial position	(238)	(416)	(93)	(113)	(135
	Group equity	267	849	849	867	89
	Minorities	0	0	0	0	
	Net equity	267	849	849	867	89
NAV DATA (Eu mn)	Properties and other assets - Book value					
10.10 271171 (20 1111)	Properties and other assets - Market value					
	NAV	267	849	849	867	89
RATIOS(%)	EBITDA margin*	nm	nm	nm	47.2%	46.69
RAIIOS(%)	EBIT margin*	11111	11111	11111	47.270	40.0
	_	00.20/	40.00/	11.00/	12.00/	15.10
	Gearing - Debt/equity	89.3%	49.0%	11.0%	13.0%	15.1
	Interest cover on EBIT	0.4	0.3	0.0	nm	nr
	Debt/Ebitda	nm	nm	nm	6.37	7.4
	Capex as % sales	0.0%	0.0%	0.0%	0.0%	0.0
	ROCE*					
	ROE*					
GROWTH RATES (%)	Sales	nm	-97.5%	21312.8%	387.5%	3.6
	EBITDA*	nm	nm	nm	nm	2.3
	EBIT*					
	Net profit	nm	-92.9%	nm	nm	47.89
			-94.8%	nm	nm	47.89

^{*} Excluding extraordinary items

Source: Intermonte SIM estimates

DETAILS

Results are not significant for DeA Capital, but the company published half year results that were in line with our estimates. The company recorded a net loss of Eu0.8mn mostly due to non cash-taxes, as pre-tax profit was positive to the tune of Eu4.2mn. We are now publishing estimates, including proportionate consolidation of Idea AI (44.36% from 4/08) and full consolidation of First Atlantic (for 2 months).

NAV stood at Eu2.78ps, with an equity value of Eu848mn and a positive net financial position of Eu262mn (vs. Eu266mn expected). The table below highlights NAV at cost, but includes the operations carried out in 2H08 as far as the NFP is concerned.

DeA Capital NAV at cost

Asset	Value (€ mln)	per share €	%	Valuation method
Santè SA	338.1	1.11	39.9%	Cost
Kenan (Migros TURK)**	81.0	0.27	9.6%	Cost
Shareholder Loan (Migros TURK)**	94.0	0.31	11.1%	Cost
ATLANTIC	72.0	0.24	8.5%	Cost
IDEA SGR	57.9	0.19	6.8%	Cost
Sigla	41.7	0.14	4.9%	Cost
IDeA I Funds	47.1	0.15	5.6%	Cost
Venture Cap. Funds	20.6	0.07	2.4%	Cost
Minor participations	3.1	0.01	0.4%	Fair value*
Fiscal Credit	0.0	0.00	0.0%	
Cash, credits and marketable sec.	93.0	0.31	11.0%	
Total	848	2.78	100.1%	
# shares (mln) net of Buy	/ Back	304.69		

^{*} updated quarterly by fund managers

Source: Intermonte SIM and Company Data

The same calculation, with GDS and Migros at market price, leaving the remaining unlisted assets at our fair value, would yield a NAV of Eu2.14 per share; however, the GDS stock price, which has the biggest impact, is no longer significant, as the real market float is extremely thin. As a matter of fact, we believe that the de-listing of GDS is considered a medium-term priority by the controlling company.





DeA Capital NAV at market price

Asset	Value (€ mln)	per share €	%	Valuation method
Santè SA	113.2	0.37	17.3%	mkt price
Kenan (Migros TURK)**	81.0	0.27	12.4%	Cost
Shareholder Loan (Migros TURK)**	94.0	0.31	14.4%	Cost
ATLANTIC	93.0	0.31	14.2%	Cost
IDEA SGR	81.1	0.27	12.4%	Cost
Sigla	12.3	0.04	1.9%	Cost
IDeA I Funds	47.1	0.15	7.2%	Cost
Venture Cap. Funds	20.6	0.07	3.2%	Cost
Minor participations	3.1	0.01	0.5%	Fair value*
Fiscal Credit	15.1	0.05	2.3%	cost
Cash, credits and marketable sec.	93.0	0.31	14.2%	
Total	653	2.14	98%	
# shares (mln) net of Buy		304.69		

^{*} quarterly updated by fund managers

Source: Intermonte SIM and Company Data

Net investment in the half year came to Eu154.4mn, of which:

- Eu57.9mn to acquire 44.3% of IDEA Alternative investment;
- Eu81.2mn, i.e. 18.5% of the holding which acquired 50.8% of Migros Turk, through Kenan investment SA;
- Eu11.1mn in capital increases at Sigla Luxembourg (Eu10.2mn) and Santé (Eu0.9mn);
- Eu4.2mn in Idea fund of funds, company investment and venture capital:
- Eu3.2mn treasury shares
- other

However, 1H08 NFP did not yet include :

- the investment in First Atlantic SGR (Eu71mn),
- part of the buyback (Eu0.5mn)
- the additional investment in Migros Turk (Eu75mn).

As a result, the NFP should amount to around Eu93mn after these investments. Additional investment capacity will be granted by a financing agreement signed in July for a maximum of Eu150mn, however. This is needed to complete the Eu1bn investment plan by 2009. This is an unsecured credit line ("Senior Term Loan Facility") expiring in 5 years, which can be used for one or more solutions within 12 months of the signing of the contract, with repayment on 30th July 2013. The rate is the 3-6 month EURIBOR rate increased by a margin with a step up mechanism, up to a maximum of 170 basis points.

With 1H08 results, the company also announced a plan to issue 1.5mn warrants (0.49% of share capital), at a subscription price of Eu 0.58, which can be exercised by 1/10/11 and 31/3/12, provided that the official price registered in a given time-frame is in line with or above Eu2.15. The exercise price of the warrants is Eu1.92.

More interestingly, we take a look at the results of the operating companies, as well as the new deals. Overall,

- GDS reported results in July, with revenues up 4% YoY in 1H08, slightly below our expectations for FY08, despite strongly outperforming market growth (+2.8% YoY). In July, the company also announced the sale and lease back of over Eu200mn of real estate and some new acquisitions, while some of the Italian assets have been sold
- MIGROS TURK reported results which are above budget and consensus (we did not have estimates). What's more, the JV which acquired the majority in February has increased its stake from 50.8%to 81.6%, buying shares on the market, and will launch a mandatory take over on the remaining shares soon;
- SIGLA reported strong YoY growth in outstanding loans (+26.6%), though this is below long term targets and our estimates:
- <u>First Atlantic</u> the acquisition will be completed in 4Q08 and therefore results are not consolidated;
- IDEA ALTERNATIVE INVESTMENTS reported Eu4.4mn net income in 1H08 (but is only consolidated as of 2Q08);

We note that overall, we expect the contribution of the alternative Investment assets (FARE+IDEA AI) in 2009 to be around Eu20mn on consolidated DeA Capital accounts. This compares with around Eu130mn paid for these two acquisitions, i.e. an attractive 6.5x PE 09.

Based on the operating companies' results, we have revised estimates and valuations. The outcome is shown in the table below, which shows how we obtain our target price.

If we were to unlock the value of the participated assets, and apply no discount to the assets below, we would reach a valuation of Eu3.48p.s.. Averaging this with the market value and the price paid to acquire the stake yields a value of Eu2.87 p.s. (net of the shares acquired in the buyback), or Eu2.53 adjusted NAV after applying a 15% discount.

DeA Capital Valuation - Adjusted NAV

Asset	Value	per share	%	Valuation method	Value	per share	%	Valuation method
	(€ mln)	€			(€ mln)	€		
Santè SA	314	1.03	34.6%	DCF & Market Price (including 07 div)	410	1.35	38.7%	DCF
Kenan (Migros TURK)**	228	0.75	25.1%	AVG Migros TURK TP	240	0.79	22.7%	AVG Migros TURK TP
ATLANTIC	93	0.31	10.3%	MULTIPLE 08 &09	93	0.31	8.8%	MULTIPLE 08 &09
IDEA SGR	81	0.27	8.9%	MULTIPLE 08 &09	104	0.34	9.9%	MULTIPLE 08 &09
Sigla	12	0.04	1.4%	MULTIPLE 08 &09	12	0.04	1.2%	MULTIPLE 08 &09
IDeA I Fund of Funds	47	0.15	5.2%	Fair value*	45	0.15	4.2%	Fair value*
Venture Cap. Funds	21	0.07	2.3%	Fair value*	28	0.09	2.6%	Fair value*
Minor participations	3	0.01	0.3%	Fair value	3	0.01	0.3%	Fair value
Fiscal Credit	15	0.05	1.7%	5Y DCF & zero	30	0.10	3.3%	5Y DCF
Cash, credits and marketable sec. 2008	93	0.31	10.3%		93	0.31	8.8%	
Total	907	2.98	100%		1059	3.48	100%	
% discount		15%						
Target price (Eu p.s.)		2.53						
% Upside/downside		27.1%						
# shares (mln) net of Buy	Back	304.69						

* quarterly updated by fund managers

Source: Intermonte SIM and Company Data






In order to eliminate or reduce the discount currently applied to the NAV by the market and to a lesser extent by us, we believe that, apart from the companies where the stake acquired has delivered positive operating results, the company should:

- De-list assets, chiefly Générale de Santé, which suffers from a very limited market float, an issue that on the one hand prevents investors acquiring a significant position, and on the other hand hinders fiscal benefits for GDS. Possibly with the aim of achieving this objective, a buyback programme was authorised in May at GDS, at a maximum price of Eu33 p.s., for up to Eu181mn over the following 12 months. We believe that the de-listing of GDS is considered a medium-term priority by its controlling shareholders.
- De-list Migros; we will outline later how this is a likely outcome, in light of the fact that the JV in which DeA Capital holds a stake has increased its share to over 81% and will launch a residual tender soon, with good chances of success.
- Utilise the Eu120mn in losses, which are not expiring;
- We believe value creation could occur, especially if in the longer term DeA Capital were to simplify the structure of the company, part of which has been completed, possibly breaking up the company, separating the Direct investment business from the Indirect one (First Atlantic and the IDEA umbrella).

While our understanding is that DeA Capital considers the delisting of GDS a medium-term objective, and the process is already underway at Migros, we do not believe that a break-up is on the cards, nor is it among management's objectives.

The current structure is highlighted below:



PEER GROUP

DeA Capital Peers	Prices as of	05/09/2008					
		2007	YID %	Today %	-1 Day %		Mkt Cap (EUR
	Price	performance	change	change	change	(reported)	mln)
Deutsche Beteiligungs	17.19	6.78%	-7.63%	-4.02%	2.46%	0.79	235.1
Dinamia	17.24	-6.31%	-14.03%	1.06%	-1.95%	0.90	206.4
Eurazeo	65.12	-14.51%	-22.08%	-1.88%	-0.67%	0.78	3464.1
GIMV	39.20	0.89%	-16.33%	-2.97%	-0.37%	0.73	908.5
Ratos	172.00	8.31%	-2.27%	-4.44%	-1.10%	1.01	2168.2
Wendel	65.50	-11.55%	-33.80%	-4.99%	-3.61%	0.82	3295.9
3i (GBp)	889.50	0.07%	-11.32%	-2.63%	-1.08%	0.83	4236.0
Candover (GBp)	2225	-4.88%	24.30%	0.45%	-1.56%	1.08	603.7
Electra (GBp)	1455.00	10.17%	-6.69%	-0.27%	-1.22%	0.73	532.5
SVG Capital (GBp)	601	-10.67%	-20.66%	-1.31%	-2.09%	0.71	1038.8
KKR PEI (USD)	12.69	-21.56%	-30.12%	-0.08%	1.60%	0.55	1803.8
avg						0.81	
		2007	YTD %	Today %	-1 Day %	P/NAV	Mkt Cap (EUR
	Price	performance	change	change	change	(reported)	mln)
M&Capitali	0.74	-18.68%	0.00%	-1.20%	-0.13%	0.67	407.7
Tamburi	1.72	-5.57%	-16.63%	-0.86%	0.52%	1.10	184.1
Mid Industry Capital	19.00	-10.18%	-15.56%	0.00%	0.00%	0.73	72.2
Cape Live	0.69	-13.24%	-24.26%	0.00%	0.00%	0.67	35.2
						0.80	
DeA Capital	1.84	-25.67%	-13.06%	-1.97%	-1.99%	0.65	563.2
LPX Europe (-1 day)	305.51	-8.76%	-21.26%	-1.97%			
MIBTEL	21241	-8.83%	-27.76%	-2.28%			
ALLSTARS	12073	-15.24%	-15.98%	-1.37%			

Source: Bloomberg and Intermonte Estimates





1H08 Results of Companies Owned or Part-Owned by DeA Capital

Générale de Santé - Santé SA

Générale de Santé reported its results in mid-July. Revenues came in at Eu512mn, +4.7% YoY, with 5.1% organic growth in the quarter (+0.9% from prices and +3.8% through better volumes and a better mix). These growth rates were below our estimates for the full year but higher than the market average, which stood at +2.8% YoY in the semester.

The EBITDA margin held up well, at 12% in the quarter (total 2Q EBITDA was Eu61mn) and 13.4% for 1H, as did EBIT, benefiting from an easy comparison with 2Q07, which was hit by costs linked to the takeover deal.

Based on these results, we have fine-tuned estimates to incorporate lower organic growth, even if we still expect the company to beat the market average. The French government recently presented a project to reform public hospitals starting from 2009 that is similar to the "regrouping" concept that is being applied to GDS. However, we believe that GDS will be able to face this change better than the competition, as it has adopted the same logic well in advance and has already developed a competitive advantage.

Generale DE Santè	41107	41100	21107	21100	2007	20005	2000	20105	% chan	ge vs Ol 2009F	LD EST. 2010F
EU mn	1H07	1H08	2H07	2H08	2007	2008E	2009E	2010E	2008E	2009E	2010E
Revenues	985	1025	1024.5	968	1906	1,993	2,130	2,271	-1%	-2%	0%
YoY		4.0%		-5.5%	9.4%	4.6%	6.9%	6.7%			
Ebitda IFRS	132.3	137.7	106.7	98	239	235	261	293	-2%	-8%	-6%
YoY		4.1%		-8.5%	0.0%	-1.6%	10.9%	12.4%			
Ebit IFRS	65.9	80	65.5	97	131.4	177	146	178	48%	-11%	-7%
YoY		21.4%		48.5%	4.3%	34.9%	-17.7%	22.2%			
Net Income	35.3	25.7	10.3	82.2	45.6	107.9	53.3	76.4	244%	-15%	-6%
YoY		-27.2%		698.0%	-80%	136.6%	-50.6%	43.2%			
NFP					-1,001.0	-856.6	-826.2	-767.3	-19%	-20%	-21%

Source: Company Data and Intermonte SIM estimates

Estimates still include the consolidation of Italian assets in 2008, while we have included the real estate sale and lease back agreement announced in July, which will generate higher rental costs and a Eu62mn pre-tax capital gain in 2008. In fact, Générale de Santé sold four hospital properties for Eu201.7mn (out of its Eu800mn in total real estate assets) and will pay Eu13.7mn in rent starting September 2008. In addition, the group announced the acquisition of the Francilienne clinic in Pontaut-Combault (77 beds), the Orangerie clinic at Perreuxsur-Marne (94 beds), and also reached an agreement to purchase a hospital centre with 292 beds in the Loire region. This acquisition appears to have come at an EV/sales multiple of around 0.5x (revenues amount to Eu60mn), while GDS trades at a multiple of 0.9x. These hospitals are expected to be consolidated by year end, while part of the Italian business (around Eu50mn in revenues, not 100% of Italian revenues, as Fleming labs and one hospital remain within the group) is expected to be de-consolidated in 2009; we expect that this part of the activities, which should bring around Eu 5-6mn Ebitda, could be sold, with a cash in of around Eu 50-60mn.

With these estimates, our valuation comes down slightly to Eu28.6 per GDS share, a value that still represents huge upside on current prices. The GDS stock price is kept down by the thin float, as the company owns 81% and 10% is owned by a single shareholder, which we would hope to see taken out at some point, also in order to enable GDS to exploit tax benefits. GDS has approved a Eu181mn buyback program, which could potentially facilitate a transaction with this single shareholder.

Gènèrale De Santè

DCF (Eu mn)	2007	2008	2009	2010	2011	2012	2013	2014	TV
EBITDA	239.0	235.3	260.9	293.2	320.7	339.7	347.5	355.1	365.7
Taxes	(40.6)	(61.2)	(50.3)	(61.5)	(71.0)	(77.5)	(80.2)	(82.8)	(79.9)
tax rate	-38.0%	-34.5%	-34.5%	-34.5%	-34.5%	-34.5%	-34.5%	-34.5%	-34.5%
Change in WC	0.1	1.5	(1.4)	1.6	1.9	1.4	4.0	0.0	0.00
Capex	(163.3)	(215.2)	(149.1)	(136.3)	(119.4)	(123.3)	(126.7)	(130.2)	(134.1)
Capex/Revenues	-2.9%	-10.8%	-7.0%	-6.0%	-5.0%	-5.0%	-5.0%	-5.0%	-5.0%
FCF	35.2	-39.6	60.1	97.1	132.3	140.3	144.5	142.0	151.7
TV									3,223
year		0.0	1.0	2.0	3.0	4.0	5.0	6.0	7.0
Discounted WACC		1.00	0.93	0.86	0.80	0.73	0.67	0.62	0.59
Discounted Free cash flow		-39.61	55.9	83.8	105.5	103.1	97.5	87.8	1,917

Discounted Free cash flows 494.0 1.916.8 Terminal value Total EV (with DCF) 2.410.7 NET FINANCIAL POS.(end 2007) -1.001.0 R.E. & Italian disposal 220 Minorities -61.7Total EQUITY 1.568 # of shares (000.000) 54.7 28.6 Value per share (Eu) 14.0 Price Upside/downside 105% WACC Terminal growth 3.0%

Source: intermonte SIM

 % stake of DeAcapital
 36%

 countervalue
 561

 Debt in GDS SA (43%)
 151

 Impact on DeaC NAV
 410

EV/SALES
EV/EBITDA
EV/Op FCF
PE
Source: intermonte SIM

TV / Total EV

2,007	2,008	2,009	2,010	2,011
1.5	1.3	1.2	1.1	1.0
10.7	10.5	9.3	8.1	7.1
33.9	122.9	21.8	15.1	11.3
34.4	23.3	29.4	20.5	14.7

As far as valuations in the sector are concerned, the Blackstone fund tried to sell one of GdS's competitors, Vitalia, for Eu1.3-1.5bn, or an EV/sales ratio of between 2.3 and 2.0 (Vitalia recorded about Eu650mn in revenues last year), compared to the 0.9x EV/sales ratio at which GdS is trading. We do not have profitability indications available for Vitalia so as to draw conclusions about GdS from this transaction. But assuming Vitalia's margins are in line with those of GdS (12.5%) or prospective margins (close to 15%), then the EV/EBITDA multiple would have been around 14-18x. In the end, the transaction did not go through; nonetheless, recent transactions in the sector support similar valuations, which would imply very significant upside to the current price, as well as a 25%+ discount to comparable companies, despite similar growth rates in some cases. Private transactions in recent years have generally occurred at around 12x EV/EBITDA.

The most comparable companies, Rhoen Klinikum and Netcare (see the peer group in the appendix) are trading at 10.3x EV/EBITDA in 2008, as compared to GDS's 7.1x. In particular, Rhoen Clinikum has an enterprise value of Eu800mn, higher than GDS, despite consolidated revenues of Eu2bn, similar profitability and a 4% growth rate.


Finally, the shareholder structure of Antonino Ligresti's investment vehicle Santé Holding, which holds 47% of GDS, has changed, as Generali has entered with a 15% stake (having paid Eu58.8mn). Mediobanca and DeA Capital's stakes have not changed. This transaction implicitly valued GDS at around Eu2.5bn, which is the same price paid by DeA Capital and Mediobanca when they first invested in GDS. Generali has been granted a way out.

Following this deal, DeA Capital has actually become the leading single shareholder in Santè SA and GDS (see-through), based on GDS control chain, as shown in the following chart:





GDS control Chain: New structure



Source: Sole 24 Ore

Migros Turk

Migros Turk, the leading food retailer in Turkey with a 22% market share, reported good 1H08 results, higher than the consensus, showing faster growth than the 15% posted in 2007 (excluding disposals) thanks in part to around 100 new store openings. The 2008-12 business plan, which was approved before the takeover, aims for a twofold increase in revenues thanks to new store openings to double the total by 2012; the plan also targets a 7% EBITDA margin. Management expects around YTL 500mn will need to be invested in order to achieve these goals.

MIGROS TURK EU mn	1H07	1H08	2H07	2H08	2007	2008E	2009E	2010E
Revenues	2028.2	2364.3	2,387	2,678	4,415	5,042	6,050	6,958
YoY		16.6%		12.2%		14.2%	20.0%	15.0%
Ebit	100.6	144.3	121	209	222	353	424	487
YoY		43.4%		71.8%		59.0%	20.0%	15.0%
Net income	79.4	127	91	86	170	213	n.a.	n.a.
YoY		59.9%		-5.3%		25.1%		
Source: Company Data, o								

Moonlight Capital, a consortium including DeA Capital, recently announced that it purchased an additional 16.3mn shares of Migros Turk from the market, thus increasing its stake from 50.1% to 81.6% through purchases made at an average price of YTL 21 per share (vs. YTL 21.24 paid for the first 50.8%). Meanwhile, the Turkish market watchdog has set a residual takeover price of YTL 21.95 per share; the adjustment in the tender call price, however, was calculated by taking into account a 27% interest rate applied on advance payments.

Should the price remain unchanged, this will result in an additional YTL 23.3mn burden for Moonlight Capital to buy the remaining 18.41% stake of the retailer. We believe that at this point, the takeover bid now has a good chance of succeeding and Moonlight capital should be able to take 100% ownership of the company and thus be able to fully exploit fiscal benefits.

For a peer group comparison, which highlights that Migros is currently trading at a 30% discount to peers on 2008 figures, refer to the Appendix.

IDEA Alternative Investment

IDEA was acquired on April 1st 2008. As of June '08, IDEA had about Eu1.8bn of assets under management (Idea Capital Funds, Investitori Associati & Wise). For more details, please refer to the report we published in February, where this acquisition is fully explained. The table below highlights the results of the company from 1/1/08, which are consolidated in DeA Capital's accounts from 1/4/08. Below, we provide highlights of our estimates for Idea Alternative Investments (100% from 1/1/08, while on DeA Capital accounts it is proportionally consolidated at 44.36% from 1/4/08).

1H07	1H08	2H07	2H08	2007	2008E	2009E	2010E
n.a.	4.2	n.a.	5.3	n.a.	9.5	9.5	9.5
						0.0%	0.0%
n.a.	2.8	n.a.	2.8	n.a.	5.60	13.2	1557%
						136%	18%
n.a.	7	n.a.	8.1	n.a.	15.10	22.7	2507%
						50%	10%
n.a.	4.4	n.a.	3.72	n.a.	8.12	13.4	15.0
						65%	12%
	n.a. n.a. n.a. n.a.	n.a. 4.2 n.a. 2.8 n.a. 7 n.a. 4.4	n.a. 4.2 n.a. n.a. 2.8 n.a. n.a. 7 n.a.	n.a. 4.2 n.a. 5.3 n.a. 2.8 n.a. 2.8 n.a. 7 n.a. 8.1 n.a. 4.4 n.a. 3.72	n.a. 4.2 n.a. 5.3 n.a. n.a. 2.8 n.a. 2.8 n.a. n.a. 7 n.a. 8.1 n.a. n.a. 4.4 n.a. 3.72 n.a.	n.a. 4.2 n.a. 5.3 n.a. 9.5 n.a. 2.8 n.a. 2.8 n.a. 5.60 n.a. 7 n.a. 8.1 n.a. 15.10 n.a. 4.4 n.a. 3.72 n.a. 8.12	n.a. 4.2 n.a. 5.3 n.a. 9.5 9.5 o.0% 0.0%

Source: Company Data and Intermonte SIM estimates

For a peer group valuation comparison, please refer to the Appendix.

Acquisition of First Atlantic

In July, DeA Capital announced the acquisition of the asset management company FARE SGR for Eu71.5mn (including its Eu+5mn NFP), a multiple of 10.3x P/E '07 without considering the strong growth expected in '08. Additional payments might arise (up to Eu11mn) if certain equity commitments are met. This multiple is in line with the alternative investment sector average but at a discount in terms of AuM multiples (the sector average is 4.4%, for this transaction it's 3.6%) thanks in part to Berenice, which has been under management since July 2008. A call option (for DeA Capital) and a put option (for Daniel Buaron) have been granted on the residual 30% of FARE Holding. These options can be exercised at market value.

First Atlantic, founded in 1998 by Daniel Buaron, is the number four Italian operator in terms of assets under management in the real estate sector. It has two main assets:

- 1) <u>First Atlantic RE SGR</u>, an asset management company that runs four real estate funds, two of which (Atlantic 1 and Atlantic 2 , i.e. the Berenice fund) are listed, with total AuM of about Eu2.8bn, and
- 2) <u>First Atlantic Real Estate S.p.A.</u>, which provides asset management and property management services for both the group's own funds and other major international funds. In 2007, these two companies turned Eu9mn in net profit, a figure expected to rise considerably in 2008.

The acquisition fits into DeA's development process in the alternative investment business. While it is currently a standalone participation, it fits into the IDeA Alternative Investments project, which already owns the AM companies Investitori Associati and Wise SGR, with AuM currently at about Eu1.9bn.

Below, we provide highlights of our estimates for First Atlantic (please note that 2007 Figures are aggregated and do not reflect holding costs).

First Atlantic R.E. cons. EU mn	11107	11100	21107	21.100	2007	2000	20005	20105
EU IIIII	1H07	1H08	2H07	2H08	2007	2008E	2009E	2010E
SGR	n.a.	n.a.	n.a.	n.a.	10.3	14.9	19.4	20.7
YoY						45%	30%	7%
Property	n.a.	n.a.	n.a.	n.a.	11.2	12.4	14.0	14.0
YoY						11%	13%	0%
Revenues	n.a.	n.a.	n.a.	n.a.	21.5	27.3	33.4	34.7
YoY						27%	22%	4%
Net income	n.a.	n.a.	n.a.	n.a.	8.5	12.7	14.0	14.5
YoY						50%	10%	4%
Source: Company Data and	Intermonte	SIM estima	ates					





For a peer group comparison, please refer to the Appendix

Overall, we expect the contribution of FARE + IDEA Alternative Investment (44.3%) in 2009 to be around Eu20mn on the consolidated DeA Capital accounts. This compares with around Eu130mn paid for the two acquisitions, i.e. an appealing 6.5x PE '09.

Sigla

Sigla, a consumer credit company, reported strong 26.6% YoY growth in revenues in 1H, though this is below its FY targets. We have therefore cut our estimates for the company (as can be seen in the following table), which is feeling the effects of the credit crunch and the economic slowdown, and has also been negatively affected by a change in equity requirements. DeA Capital injected Eu10.1mn into Sigla and brought its stake to 35% from 30%.

SIGLA - P&L (Eu mn)									% chan	ige vs O	LD EST.
Eu mn	1H07	1H08	2H07	2H08	2007	2008E	2009E	2010E	2008E	2009E	2010E
(505)									000/	050/	0001
Oustanding loans (EOP)	128.7	161.8	170.0	211.5	170.0	211.5	267.8	342.8	-20%	-25%	-23%
YoY		26%		24%	100%	24%	27%	28%			
Revenues	12.0	15.4	12.0	17.4	24.0	32.8	42.1	54.2	-16%	-23%	-22%
YoY		28%		45%	193%	37%	28%	29%			
Net Income	n.a.	-2.9	0.1	0.0	-2.8	-2.9	-0.3	2.6	n.m.	-114%	-42%
YoY		n.m.		n.m.	n.m.	n.m.	n.m.	-1086%			
Source: Company Data a	nd Intorm	anta SIMA ac	timatoc								

Source: Company Data and Intermonte SIM estimates

Our valuation has been adjusted accordingly.

APPENDIX:

Générale de Santè : Peer group

Peer group Générale de Santè Minibase in EUR as of 05/09/08

			Mkt Cap	Е	V/EBITDA			PE	
Company	Crcy	Price	(Eu mn)	2007	2008	2009	2007	2008	2009
Generale De Sante (cons))	EUR - Euro	12.2	666	6.8x	7.1x	6.7x	11.4x	15.0x	13.6x
Care Uk	GBP - UK Pound Sterling	4.2	258	9.7x	8.2x	7.0x	11.9x	13.0x	11.1x
Curanum AG	EUR - Euro	3.8	122	7.9x	7.9x	7.2x	23.4x	12.2x	10.2x
Orpea SA	EUR - Euro	33.9	1,243	21.8x	17.9x	15.4x	33.6x	28.3x	22.7x
Rhoen Klinikum	EUR - Euro	22.3	2,310	11.3x	10.8x	10.0x	21.7x	19.5x	17.4x
Netcare Ltd.	ZAR - South African Rai	0.7	1,372	n.m.	10.6x	10.6x	10.2x	13.9x	11.1x
Athens Medical Centre	EUR - Euro	2.0	171	n.m.	7.0x	7.0x	11.2x	9.9x	10.2x
Mediclin AG	EUR - Euro	2.8	88	n.m.	9.2x	9.2x	15.5x	15.7x	8.0x
Marseille Kliniken AG	EUR - Euro	8.5	103	n.m.	4.9x	4.9x	9.9x	9.5x	7.2x
Southern Cross Healthcare Group	Plc GBP - UK Pound Sterling	1.8	330	n.m.	4.6x	4.6x	6.9x	6.8x	6.4x
Total			6,663						
Average				10.7x	8.6x	8.1x	15.2x	14.8x	11.9x
Median				8.8x	8.0x	7.1x	16.8x	17.2x	13.0x
Avg x mkt cap					11.0x	10.2x	18.9x	18.1x	15.3x

Source: JCF Consensus





Migros: Peer group

Peer group Minibase in EUR as of 05/09/08

			Mid Con	E) /	/ EDITO			D / E	
Company	Crcy	Price	Mkt Cap I.c.	2008	/ EBITD 2009	A 2010	2008	P / E 2009	2010
Company	Olcy	rnec	1.0.	2000	2007	2010	2000	2007	2010
Ahold (Kon.)	EUR - Euro	8.73	10,405	6.7x	6.0x	5.4x	13.1x	11.5x	10.4x
Carrefour SA	EUR - Euro	34.01	23,970	5.8x	5.3x	4.9x	12.1x	11.2x	10.2x
Casino Guichard Perrachon SA	EUR - Euro	62.76	6,789	5.8x	5.5x	5.2x	12.7x	11.7x	10.5x
Colruyt SA	EUR - Euro	177.24	5,911	10.0x	9.2x	8.6x	18.2x	16.7x	15.4x
Delhaize Group SA	EUR - Euro	43.09	4,321	5.0x	4.7x	4.4x	10.6x	9.9x	9.3x
Metro AG	EUR - Euro	37.69	12,316	4.7x	4.4x	4.1x	12.3x	10.6x	9.5x
Tesco	GBP - UK Pound Sterling	4.57	35,932	8.5x	7.6x	6.9x	13.4x	11.9x	10.4x
Wal Mart Stores Inc	USD - US Dollar	42.58	167,928	9.2x	8.6x	7.9x	17.4x	15.7x	14.2x
Costco Wholesale Inc	USD - US Dollar	48.0	20,860	11.1x	10.2x	9.3x	23.6x	21.1x	18.4x
Total			63,712						
Average				7.4x	6.8x	6.3x	14.8x	13.4x	12.1x
Median				6.7x	6.0x	5.4x	13.1x	11.7x	10.4x
Average per CAP				6.1x	5.6x	5.2x	12.8x	11.6x	10.6x
Wal-Mart de Mexico S.A.B. de C.	VMXN - Mexican Peso	2.45	20,840	12.2x	10.7x	9.2x	20.2x	17.0x	14.6x
Grupo Famsa S.A. de C.V.	MXN - Mexican Peso	1.8	597	8.2x	7.4x	5.2x	13.3x	8.7x	6.7x
X5 Retail Group N.V.	USD - US Dollar	15.91	4,194	10.2x	7.7x	6.1x	20.4x	16.1x	12.1x
Seventh Continent	USD - US Dollar	17.8	1,338	13.8x	10.6x	10.1x	21.3x	17.7x	17.2x
Magnit JSC	USD - US Dollar	24.36	1,754	8.2x	6.3x	5.2x	19.7x	14.4x	11.0x
Total			253,442						
Average				9.2x	8.0x	7.0x	17.3x	14.5x	12.5x
Median				8.5x	7.6x	6.3x	17.4x	14.4x	12.1x
5				0.4	4.0	4.0	0.0	0.5	
Deviazione standard Migros Turk	TRY - New Turkish Lira	12.1	2.157	2.4x 10.2x	1.8x 10.2x	1.9x 7.9x	3.9x 18.5x	3.5x 16.5x	3.4x 14.9x
BIM Birlesik Magazalar A.S.		23.39	1.775	10.2x	10.2x	7.9x		16.9x	12.6x
J	TRY - New Turkish Lira	3.86	432	13.4X n.d.	n.d.	n.d.	21.4x n.d.	n.d.	12.6x
Tesco-Kipa Kitle Pazarlama Ticare Average	e ikt - ivew iufkish Lifa	3.80	432	11.8x	10.5x	7.9x	20.0x	16.7x	13.8x
Median				11.8x	10.5x	7.9x 7.9x	20.0x 20.0x	16.7x	13.8x

^{*} based on Ebitda according to Swisscom Definition - before extr.

**Source: Intermonte SIM estimates, JCF consensus*

IDEA Alternative Investments & FARE Peer group

IDEA AI & FARE

Peer group Minibase in EUR as of 05/09/08

			Mkt Cap	AUM	P/AUM			
Company	Crcy	Price	l.c.	Eu bn		2007	2008	2009
Traditional Asset Manager	'S							
Aberdeen Asset Manager	m EUR - Euro	1.63	1,168	103	1.1%	10.8x	12.7x	10.1x
Anima S.G.R.p.A.	EUR - Euro	1.18	124	10	1.2%	7.3x	7.0x	41.9x
Azimut Holding SpA	EUR - Euro	5.90	842	15	5.7%	8.3x	13.9x	8.6x
F&C Asset Management	GBP - UK F	1.13	555	99	0.6%	8.1x	9.5x	8.5x
Henderson Group	EUR - Euro	1.60	1,150	10	12.1%	10.5x	11.8x	11.5x
Rathbone Brothers	EUR - Euro	11.46	490	13	3.8%	10.5x	12.0x	11.7x
Schroders	GBP - UK F	11.83	3,273	138	2.4%	8.4x	12.1x	11.2x
Alternative Asset Manage	rs							
Blackstone Group Lp		11.52	1.793	19	9.4%	10.4x	41.9x	14.3x
Fortress Investment Group	ILC	6.51	616	20	3.1%	9.5x	15.7x	8.2x
GLG Partners Inc.		5.61	1,378	21	6.5%	9.3x	15.8x	9.3x
Man Group		6.10	10,398	22	47.0%	10.5x	11.8x	9.9x
Partners Group Holding A	G	94.20	2.515	23	10.9%	17.5x	16.9x	14.1x
Ashmore Group Plc	_	3.03	2,145	24	8.9%	17.0x	13.3x	11.7x
Bluebay Asset Manageme	ent Plc	3.20	619	11	5.8%	12.5x	14.3x	12.4x
Charlemagne Capital Ltd		0.39	111	4	3.2%	2.8x	7.9x	5.7x
Hargreaves Lansdown Plo		2.30	1,090	11	10.3%	26.4x	20.9x	18.2x
RAB Capital Plc		0.45	226	5	4.7%	5.3x	13.5x	11.0x
Average					8.0%	10.9x	14.8x	12.8x
Median					5.7%	10.4x	13.3x	11.2x
RE service Co								
Colliers CRE PLc	EUR - Euro	0.47	22			2.5x	4.9x	2.3x
Savills	EUR - Euro	3.42	451			5.5x	10.0x	9.8x
Dtz Holdings	GBP - UK P	1.40	83			5.9x	7.9x	5.4x
Rok Plc	GBP - UK P	1.09	195			6.2x	6.5x	6.0x
Average						5.0x	7.3x	5.9x
Median						5.7x	7.2x	5.7x

Source: Intermonte SIM estimates, JCF consensus





DISCLAIMER (for more details go to http://intermonte.it/ disclosures.asp)

IMPORTANT DISCLOSURES

The reproduction of the information, recommendations and research produced by Intermonte SIM contained herein and of any its parts is strictly prohibited. None of the contents of this document may be shared with third parties without authorisation from Intermonte.

This report is directed exclusively at market professional and other institutional investors (Institutions) and is not for distribution to person other than "Institution" ("Non-Institution"), who should not rely on this material. Moreover, any investment or service to which this report may relate will not be made available to Non-Institution.

The information and data in this report have been obtained from sources which we believe to be reliable, although the accuracy of these cannot be guaranteed by the Intermonte. In the event that there be any doubt as to their reliability, this will be clearly indicated. The main purpose of the report is to offer up-to-date and accurate information in accordance with regulations in force covering "recommendations" and is not intended nor should it be construed as a solicitation to buy or sell securities.

This disclaimer is constantly updated on Intermonte's website www.intermonte.it under DISCLOSURES. Valuations and recommendations can be found in the text of the most recent research and/or reports on the companies in question.

For each company mentioned in this report the respective research analyst hereby certifies that all of the views expressed in this research report accurately reflect the analyst's personal views about any or all of the subject issuer (s) or securities. The analyst (s) also certify that no part of their compensation was, is or will be directly or indirectly related to the specific recommendation or view in this report.

The analyst (s) responsible for preparing this research report receive(s) compensation that is based upon various factors, including Intermonte's total profits, a portion of which is generated by Intermonte's corporate finance activities, although this is minimal in comparison to that generated by brokerage activities. Intermonte's corporate finance activities, although this is minimal in comparison to that generated by brokerage activities. Intermonte's internal procedures and codes of conduct are aimed to ensure the impartiality of its financial analysis. The exchange of information between the Corporate Finance sector and the Research Department is prohibited, as is the exchange of information between the proprietary equity desk in order to prevent conflicts of interest when recommendations are made

GUIDE TO FUNDAMENTAL RESEARCH

Reports on all companies listed on the S&PMIB40 Index, most of those on the MIDEX Index and the main small caps (regular coverage) are published at least once per quarter to

comment on results and important newsflow.

A draft copy of each report may be sent to the subject company for its information (without target price and/or recommendations), but unless expressly stated in the text of the report, no changes are made before it is published.

Explanation of our ratings system:

BUY: stock expected to outperform the market by over 25% over a 12 month period;
OUTPERFORM: stock expected to outperform the market by between 10% and 25% over a 12 month period;
NEUTRAL: stock performance expected at between +10% and - 10% compared to the market over a 12 month period;
UNDERPERFORM: stock expected to underperform the market by between -10% and -25% over a 12 month period;
SELL: stock expected to underperform the market by over 25% over a 12 month period.

The stock price indicated is the reference price on the day prior to the publication of the report

CURRENT INVESTMENT RESEARCH RATING DISTRIBUTIONS

Intermonte SIM is authorised by CONSOB to provide investment services and is listed at n° 246 in the register of brokerage firms.

As at June 30th 2008 Intermonte's Research Department covered 151 companies. Intermonte's distribution of stock ratings is as follows

OUTPERFORM:26.49% NEUTRAL: 26.81% UNDERPERFORM: 19.21%

SELL: 1 32%

The distribution of stock ratings for companies which have received corporate finance services from Intermonte in the last 12 months (24 in total) is as follows

OUTPERFORM: 29.17% NEUTRAL: 33.33% UNDERPERFORM: 0.0%

SELL: 0.0%

CONFLICT OF INTEREST

In order to disclose its possible conflicts of interest Intermonte SIM states that:

- r to disclose its possible conflicts of interest intermonte SIM states that: within the last year, Intermonte SIM managed or co-managed or is co-managing (see companies indicated in **bold** type) an Institutional Offering of the securities of the following Companies: Arkimedica, IT Holding (private placement), Monti Ascensori (private placement), Pierrel (private placement); Intermonte SIM is Sponsor in accordance with the Italian Securities Markets regulations, with the related obligation of coverage and distribution of research, of the following Companies: Arkimedica, Biancamano, Caleffi, Conafi, Omnia Network, RDM Realty: Intermonte SIM is Specialist, in accordance with the Italian Securities Markets regulations, with the related obligation of coverage and distribution of research, of the following Companies: Biancamano, Caleffi, Cogene, Datalogic, DeA Capital, Digital Bros, Dmail, EEMS, Fiera Milano, FMR Art'è, Kerself, M&C Management e Capitali, Monti Ascensori, Pierrel, Reno de Medici, Realty Valiog, Saes Getters, Servizi Italia, TAS, Trevisan, TXT e-solutions.

DETAILS ON STOCK RECOMMENDATION

Stock NAME	DEA CAPITAL		
Current Recomm:	BUY	Previous Recomm:	BUY
Current Target (Eu):	2.55	Previous Target (Eu):	2.55
Current Price (Eu):	1.84	Previous Price (Eu):	2.02
Date of report:	08/09/2008	Date of last report:	28/07/2008

INTERMONTE SIM is MIFID compliant - for our Best Execution Policy please check our Website www.intermonte.it/mifid

Further information is available